Richard G. Wunderink, MD

Dr.
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure: Arsanis: Consultant, Other Financial or Material Support, Institution received funding for clinical trial enrollment. RGW received consultation fees for clinical trial design
KBP Biosciences: Consultant
Meiji-Seiko: Consultant
Melinta/The Medicines Company: Consultant, Other Financial or Material Support, Institution received funding for clinical trial enrollment. RGW received consultation fees for clinical trial design
Merck: Consultant, Institution received funding for clinical trial enrollment. RGW received consultation fees for clinical trial design
Microbiotix: Consultant
Pfizer: Advisor or Review Panel member
Polyphor: Other Financial or Material Support, Institution received funding for clinical trial enrollment. RGW received consultation fees for clinical trial design
Shionogi: Consultant, Other Financial or Material Support, Institution received funding for clinical trial enrollment. RGW received consultation fees for clinical trial design

Presentation(s):

• LB4 - Efficacy and Safety of Cefiderocol versus High-Dose Meropenem in Patients with Nosocomial Pneumonia – Results of a Phase 3 Randomized, Multicenter, Double-Blind, Non-Inferiority Study

  Thursday, October 3
  2:15 PM – 2:25 PM

• 2841 - A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate (TZD) and Linezolid (LZD) for Treatment of Ventilated Gram-Positive (G+) Nosocomial Pneumonia

  Saturday, October 5
  2:30 PM – 2:45 PM